Literature DB >> 22766657

Overtreatment and undertreatment of hyperlipidemia in the outpatient setting.

Ashish Verma1, Paul Visintainer, Mohamed Elarabi, Siddharth Wartak, Michael B Rothberg.   

Abstract

BACKGROUND: National guidelines recommend lipid-lowering therapy for patients with coronary heart disease (CHD), its equivalent (eg, diabetes mellitus, peripheral arterial disease, cerebrovascular disease), and those at high risk of CHD. Quality-of-care studies demonstrate that patients at high risk of CHD are undertreated. Overtreatment of patients at low risk of CHD remains relatively unexplored. Our study aimed to determine patient characteristics associated with under- and overtreatment of hyperlipidemia.
METHODS: We conducted a retrospective chart review of patients aged 35 to 80 years attending an inner-city ambulatory teaching clinic. We noted patients' 10-year cardiovascular risk based on the Framingham Heart Study equation, other patient demographics, pretreatment lipid levels, and whether they received a prescription for lipid-lowering therapy.
RESULTS: Of 676 patients included, 46% were at high (>15% for 10 years) and 37% were at low (<5%) risk. Of the patients at high risk for CHD, 34% received no drug therapy, including 5% of patients with known CHD; 37% of patients with diabetes mellitus; and 59% of patients without CHD equivalents. Undertreatment was associated with lower low-density lipoprotein (LDL; odds ratio [OR] per 30 mg/dL 2.7, confidence interval [CI] 2.0-3.6), fewer risk factors (OR per risk factor 1.5 CI 1.1-2.1), and not receiving other preventive care interventions (OR 2.1, CI 1.0-4.5). Of 247 patients at low risk for CHD, 8% received drug therapy. Overtreatment was associated with higher LDL (OR per 30 mg/dL 3.0, CI 1.7-5.3) and more cardiac risk factors (OR per risk factor 3.1, CI 1.4-6.7). Age, race, sex, and specific risk factors were not associated with overtreatment or undertreatment.
CONCLUSIONS: Both overtreatment and under-treatment are common. Physicians' decisions appear to reflect LDL values and number of risk factors rather than calculated cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22766657     DOI: 10.1097/SMJ.0b013e318259bad3

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  8 in total

1.  Lipid-Lowering Prescription Patterns in Patients With Diabetes Mellitus or Cardiovascular Disease.

Authors:  Alanna M Chamberlain; Sarah S Cohen; Jill M Killian; Keri L Monda; Susan A Weston; Ted Okerson
Journal:  Am J Cardiol       Date:  2019-07-15       Impact factor: 2.778

2.  Clinically relevant quality measures for risk factor control in primary care: a retrospective cohort study.

Authors:  Stefan Weiler; Armin Gemperli; Tinh-Hai Collet; Douglas C Bauer; Lukas Zimmerli; Jacques Cornuz; Edouard Battegay; Jean-Michel Gaspoz; Eve A Kerr; Drahomir Aujesky; Nicolas Rodondi
Journal:  BMC Health Serv Res       Date:  2014-07-15       Impact factor: 2.655

3.  The low indexes of metabolism intervention trial (LIMIT): design and baseline data of a randomized controlled clinical trial to evaluate how alerting primary care teams to low metabolic values, could affect the health of patients aged 75 or older.

Authors:  Nir Tsabar; Yan Press; Johanna Rotman; Bracha Klein; Yonatan Grossman; Maya Vainshtein-Tal; Sophia Eilat-Tsanani
Journal:  BMC Health Serv Res       Date:  2018-01-05       Impact factor: 2.655

4.  Monitoring Prevalence, Treatment, and Control of Metabolic Conditions in New York City Adults Using 2013 Primary Care Electronic Health Records: A Surveillance Validation Study.

Authors:  Lorna E Thorpe; Katharine H McVeigh; Sharon Perlman; Pui Ying Chan; Katherine Bartley; Lauren Schreibstein; Jesica Rodriguez-Lopez; Remle Newton-Dame
Journal:  EGEMS (Wash DC)       Date:  2016-12-15

5.  PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.

Authors:  Alanna M Chamberlain; Yan Gong; Kathryn McAuliffe Shaw; Jiang Bian; Wen-Liang Song; MacRae F Linton; Vivian Fonseca; Eboni Price-Haywood; Emily Guhl; Jordan B King; Rashmee U Shah; Jon Puro; Elizabeth Shenkman; Pamala A Pawloski; Karen L Margolis; Adrian F Hernandez; Rhonda M Cooper-DeHoff
Journal:  J Am Heart Assoc       Date:  2019-05-07       Impact factor: 5.501

6.  Patient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK general practice: a national retrospective cohort study.

Authors:  Jianhua Wu; Shihua Zhu; Guiqing Lily Yao; Mohammed A Mohammed; Tom Marshall
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

7.  A prospective study of statin use and mortality among 67,385 blacks and whites in the Southeastern United States.

Authors:  Loren Lipworth; Sergio Fazio; Edmond K Kabagambe; Heather M Munro; Victor C Nwazue; Robert E Tarone; Joseph K McLaughlin; William J Blot; Uchechukwu Ka Sampson
Journal:  Clin Epidemiol       Date:  2013-12-19       Impact factor: 4.790

8.  Key factors influencing the prescribing of statins: a qualitative study among physicians working in primary healthcare facilities in Indonesia.

Authors:  Sylvi Irawati; Sari Prayudeni; Riris Rachmawati; I Wayan Wita; Bob Willfert; Eelko Hak; Katja Taxis
Journal:  BMJ Open       Date:  2020-06-15       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.